New screening method reveals why Alzheimer’s drugs often fail
Researchers have developed a new method to screen drugs for Alzheimer’s disease, shedding light on why current drugs have failed and identifying novel drug targets.
List view / Grid view
Researchers have developed a new method to screen drugs for Alzheimer’s disease, shedding light on why current drugs have failed and identifying novel drug targets.
NanoTemper Technologies has announced the launch of Spectral Shift technology with its Dianthus instrument.
25 March 2022 | By Bruker Daltonics
Watch our free on-demand webinar to discover how the new timsTOF MPP product solution, with its dedicated MALDI PharmaPulse 2023 HTS software suite, improves data quality and accelerates high-throughput screening in drug discovery.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Novel research has shown that morphological fingerprinting could help identify side effects of new bioactive compounds in drug discovery.
Researchers at the University of Texas have redesigned a key component of a CRISPR-based gene-editing tool.
A new study modelled chlamydia and HPV co-infection in patient-derived ectocervix organoids to reveal distinct cellular reprogramming.
Scientists have demonstrated how automated, high-throughput life science experiments can be replicated on a modest budget.
A new report says that the global lab automation market is set to grow significantly until 2031, due to advanced drug development.
21 February 2022 | By Yokogawa Deutschland GmbH
Watch our free on-demand webinar to discover how fully automated imaging and image analysis can provide the unprecedented possibility to follow single viral particles, including for SARS-CoV-2.
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
The first patient-derived stem cell model to research eye conditions related to oculocutaneous albinism (OCA) has been created.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
Benefits and key considerations of using human iPSC-derived disease models in drug discovery.
Knowledge is power – for scientists at least – and thanks to collaborative research from a UK and German university, we now have better understanding of the SARS-CoV-2 Omicron virus, including how it behaves and effective means of treatment.